X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14017) 14017
Book / eBook (127) 127
Magazine Article (30) 30
Web Resource (21) 21
Book Chapter (18) 18
Publication (10) 10
Conference Proceeding (5) 5
Dissertation (4) 4
Book Review (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13554) 13554
female (7657) 7657
male (7231) 7231
middle aged (6061) 6061
adult (6032) 6032
hematology (5893) 5893
oncology (5216) 5216
hematologic neoplasms - therapy (4836) 4836
aged (4399) 4399
adolescent (3211) 3211
cancer (3054) 3054
transplantation (2850) 2850
leukemia (2470) 2470
treatment outcome (2339) 2339
hematologic neoplasms - drug therapy (2237) 2237
child (2164) 2164
hematologic neoplasms - complications (2088) 2088
immunology (2084) 2084
retrospective studies (2014) 2014
chemotherapy (1829) 1829
risk factors (1617) 1617
young adult (1578) 1578
hematopoietic stem cell transplantation (1564) 1564
transplantation, homologous (1514) 1514
animals (1473) 1473
stem cells (1456) 1456
child, preschool (1421) 1421
hematopoietic stem cells (1405) 1405
care and treatment (1364) 1364
prognosis (1337) 1337
bone-marrow-transplantation (1316) 1316
hematologic neoplasms - pathology (1282) 1282
hematologic neoplasms - mortality (1278) 1278
health aspects (1237) 1237
aged, 80 and over (1209) 1209
antineoplastic agents - therapeutic use (1184) 1184
research (1184) 1184
therapy (1172) 1172
acute myeloid-leukemia (1141) 1141
analysis (1132) 1132
antineoplastic combined chemotherapy protocols - therapeutic use (1126) 1126
hematologic neoplasms - immunology (1102) 1102
hematologic malignancies (1096) 1096
hematologic diseases - chemically induced (1062) 1062
hematopoietic stem cell transplantation - adverse effects (1043) 1043
hematology, oncology and palliative medicine (1002) 1002
medicine (998) 998
lymphoma (974) 974
mortality (968) 968
survival analysis (949) 949
hematologic neoplasms - genetics (930) 930
versus-host-disease (927) 927
prospective studies (910) 910
research article (897) 897
survival rate (896) 896
infant (893) 893
bone marrow (889) 889
follow-up studies (887) 887
stem-cell transplantation (861) 861
antineoplastic agents - adverse effects (823) 823
survival (819) 819
medicine & public health (809) 809
patients (798) 798
lymphomas (796) 796
antineoplastic combined chemotherapy protocols - adverse effects (795) 795
hematopoietic stem cell transplantation - methods (783) 783
disease-free survival (761) 761
diagnosis (758) 758
science (750) 750
hematologic cancers and related disorders (745) 745
children (739) 739
multidisciplinary sciences (736) 736
tumors (728) 728
hematologic neoplasms - diagnosis (717) 717
acute lymphoblastic-leukemia (707) 707
incidence (686) 686
time factors (680) 680
neoplasms - therapy (672) 672
pharmacology & pharmacy (666) 666
blood (653) 653
transplantation conditioning - methods (649) 649
pediatrics (646) 646
stem cell transplantation (642) 642
risk (637) 637
bone marrow transplantation (633) 633
graft vs host disease - prevention & control (631) 631
medical research (624) 624
neoplasms - drug therapy (624) 624
disease (620) 620
infectious diseases (611) 611
cancers and neoplasms (609) 609
hematologic neoplasms - metabolism (604) 604
mice (601) 601
apoptosis (583) 583
combined modality therapy (559) 559
recurrence (558) 558
hematologic neoplasms - blood (536) 536
graft vs host disease - etiology (530) 530
transplantation conditioning (523) 523
chronic lymphocytic-leukemia (520) 520
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (39) 39
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (29) 29
Online Resources - Online (28) 28
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
St. Michael's Hospital - Stacks (3) 3
Gerstein Science - Circulation Desk (2) 2
Markham Stouffville Hospital - Stacks (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Reference (2) 2
Toronto East General Hospital - Stacks (2) 2
Gerstein Science - Periodical Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Online (1) 1
Mt Sinai Hospital - Online (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Reference (1) 1
Women's College Hospital - Online (1) 1
Women's College Hospital - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13291) 13291
Japanese (263) 263
French (211) 211
Chinese (162) 162
German (155) 155
Spanish (104) 104
Russian (78) 78
Polish (48) 48
Italian (42) 42
Czech (16) 16
Hungarian (15) 15
Portuguese (14) 14
Finnish (11) 11
Danish (10) 10
Dutch (9) 9
Hebrew (8) 8
Croatian (4) 4
Korean (4) 4
Norwegian (4) 4
Serbian (3) 3
Turkish (3) 3
Arabic (2) 2
Romanian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lung Cancer, ISSN 1525-7304, 2017, Volume 18, Issue 5, pp. 543 - 550.e3
Background –Patients with prior malignancies may be at increased risk for non-small cell lung cancer (NSCLC). However, the extent of risk is unknown for many... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | NSCLC | Survivor | Radiation | Screening criteria | Smoking | SURGERY | HODGKINS LYMPHOMA SURVIVORS | RADIATION-THERAPY | HORMONE USE | BREAST-CANCER | WOMEN | ONCOLOGY | RADIOTHERAPY | CARCINOMA | HISTORY | Melanoma - epidemiology | Smoking - adverse effects | Lung Neoplasms - ethnology | United States - epidemiology | Prostatic Neoplasms - radiotherapy | Kidney Neoplasms - epidemiology | Pancreatic Neoplasms - epidemiology | Neoplasms, Second Primary - ethnology | Humans | Middle Aged | Thyroid Neoplasms - epidemiology | Uterine Neoplasms - epidemiology | Colorectal Neoplasms - radiotherapy | Male | Hematologic Neoplasms - epidemiology | Incidence | Hematologic Neoplasms - radiotherapy | Head and Neck Neoplasms - epidemiology | Female | Uterine Neoplasms - radiotherapy | Urinary Bladder Neoplasms - epidemiology | Adenocarcinoma - radiotherapy | Breast Neoplasms - epidemiology | Colorectal Neoplasms - epidemiology | SEER Program | Risk Factors | Melanoma - radiotherapy | Carcinoma, Non-Small-Cell Lung - epidemiology | Pancreatic Neoplasms - radiotherapy | Carcinoma, Non-Small-Cell Lung - ethnology | Thyroid Neoplasms - radiotherapy | Kidney Neoplasms - radiotherapy | Neoplasms, Second Primary - epidemiology | Prostatic Neoplasms - epidemiology | Head and Neck Neoplasms - radiotherapy | Breast Neoplasms - radiotherapy | Urinary Bladder Neoplasms - radiotherapy | Lung Neoplasms - epidemiology | Smoking - epidemiology | Sex Factors | Aged | Adenocarcinoma - epidemiology | screening criteria | radiation | smoking | survivor
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 5, pp. 782 - 790
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2013, Volume 10, Issue 5, pp. 256 - 266
The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies... 
CELL LUNG-CANCER | HISTONE DEACETYLASE INHIBITOR | PHASE-II TRIAL | POLYCYTHEMIA-VERA | DNA METHYLATION | ONCOLOGY | SUBEROYLANILIDE HYDROXAMIC ACID | GERMLINE EPIMUTATION | ESSENTIAL THROMBOCYTHEMIA | MYELODYSPLASTIC SYNDROMES | CHRONIC MYELOMONOCYTIC LEUKEMIA | Hematologic Neoplasms - therapy | Humans | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors | Promoter Regions, Genetic - drug effects | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Neoplasms - therapy | Molecular Targeted Therapy - trends | Multicenter Studies as Topic | Neoplasms - genetics | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Drug Therapy, Combination | Molecular Targeted Therapy - methods | Myelodysplastic Syndromes - drug therapy | Drug Administration Schedule | Enzyme Inhibitors - pharmacology | Clinical Trials as Topic | Combined Modality Therapy | Genetic Therapy - trends | DNA, Neoplasm - drug effects | Enzyme Inhibitors - therapeutic use | Forecasting | Neoplasms - drug therapy | Animals | Hematologic Neoplasms - drug therapy | Histone Deacetylase Inhibitors - pharmacology | Hematologic Neoplasms - genetics | Histone Deacetylase Inhibitors - therapeutic use | Myelodysplastic Syndromes - genetics | DNA, Neoplasm - genetics | DNA Methylation - drug effects | Drug Screening Assays, Antitumor | Genetic Therapy - methods | Epigenetic inheritance | Care and treatment | Genetic aspects | Research | Gene expression | Tumors
Journal Article
Annals of oncology, ISSN 0923-7534, 2007, Volume 18, Issue 11, pp. 1782 - 1792
In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged... 
Radionuclide therapy | Transarterial radionuclide therapy | Radiopharmaceuticals | Peptide receptor radionuclide therapy | Radioiodine therapy | Radio immunotherapy | MURINE MONOCLONAL-ANTIBODY | I-131 METAIODOBENZYLGUANIDINE | radioimmunotherapy | peptide receptor radionuclide therapy | DIFFERENTIATED THYROID-CARCINOMA | CARCINOEMBRYONIC-ANTIGEN RADIOIMMUNOTHERAPY | radiopharmaceuticals | RANDOMIZED CONTROLLED TRIAL | radioiodine therapy | PHASE-II TRIAL | HEPATOCELLULAR-CARCINOMA | radionuclide therapy | ONCOLOGY | HIGH-DOSE I-131-METAIODOBENZYLGUANIDINE | REFRACTORY LOW-GRADE | RECEPTOR RADIONUCLIDE THERAPY | transarterial radionuclide therapy | Thyroid Neoplasms - diagnosis | Prognosis | Hematologic Neoplasms - mortality | Humans | Male | Neuroblastoma - mortality | Ovarian Neoplasms - mortality | Ovarian Neoplasms - radiotherapy | Nuclear Medicine - trends | Hematologic Neoplasms - radiotherapy | Ovarian Neoplasms - diagnostic imaging | Female | Neoplasms - radiotherapy | Nuclear Medicine - standards | Thyroid Neoplasms - mortality | Hematologic Neoplasms - diagnostic imaging | Risk Assessment | Neoplasms - mortality | Neuroblastoma - diagnostic imaging | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Neoplasms - diagnostic imaging | Forecasting | Neuroblastoma - radiotherapy | Radionuclide Imaging | Survival Analysis | 3-Iodobenzylguanidine - therapeutic use | Indium Radioisotopes - therapeutic use | Radiopharmaceuticals - therapeutic use | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal Article
Drug Resistance Updates, ISSN 1368-7646, 2016, Volume 29, pp. 90 - 106
...), the first nanomedicine to be approved for cancer therapy, and discuss the gap between its potent antitumor activity in preclinical studies and its comparatively modest achievements in clinical... 
Infectious Disease | Hematology, Oncology and Palliative Medicine | Liposome | Anthracyclines | Chemotherapy | Drug delivery | Nanomedicine | ADVANCED BREAST-CANCER | STERICALLY STABILIZED LIPOSOMES | SOFT-TISSUE SARCOMAS | PROLONGED CIRCULATION TIME | T-CELL LYMPHOMA | OVARIAN-CANCER | KAPOSIS-SARCOMA | RANDOMIZED PHASE-III | GLYCOL-COATED LIPOSOMES | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | Antibiotics, Antineoplastic - pharmacology | Liposomes - administration & dosage | Sarcoma, Kaposi - metabolism | Theranostic Nanomedicine - trends | Humans | Ovarian Neoplasms - pathology | Male | Hematologic Neoplasms - pathology | Breast Neoplasms - metabolism | Sarcoma, Kaposi - drug therapy | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Drug Compounding | Female | Ovarian Neoplasms - metabolism | Antibiotics, Antineoplastic - pharmacokinetics | Ovarian Neoplasms - drug therapy | Hematologic Neoplasms - metabolism | Polyethylene Glycols - pharmacology | Drug Administration Schedule | Polyethylene Glycols - pharmacokinetics | Clinical Trials as Topic | Multiple Myeloma - metabolism | Breast Neoplasms - drug therapy | Doxorubicin - pharmacokinetics | Sarcoma, Kaposi - pathology | Multiple Myeloma - pathology | Breast Neoplasms - pathology | Hematologic Neoplasms - drug therapy | Doxorubicin - pharmacology | Medical colleges | Usage | Sarcoma | Multiple myeloma | Adjuvant treatment | Jewish schools | Permeability | Ovarian cancer | Analysis | Lymphomas | Health aspects | Cancer | Drugs | Medical research | Drug delivery systems | Vehicles | Medicine, Experimental | Nanotechnology
Journal Article